ZA200502613B - Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents - Google Patents
Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agentsInfo
- Publication number
- ZA200502613B ZA200502613B ZA200502613A ZA200502613A ZA200502613B ZA 200502613 B ZA200502613 B ZA 200502613B ZA 200502613 A ZA200502613 A ZA 200502613A ZA 200502613 A ZA200502613 A ZA 200502613A ZA 200502613 B ZA200502613 B ZA 200502613B
- Authority
- ZA
- South Africa
- Prior art keywords
- inflammatory
- fatty alcohols
- immunomodulatory agents
- basic esters
- esters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41715702P | 2002-10-10 | 2002-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200502613B true ZA200502613B (en) | 2006-10-25 |
Family
ID=32093977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200502613A ZA200502613B (en) | 2002-10-10 | 2003-10-09 | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
Country Status (15)
Country | Link |
---|---|
US (1) | US8987263B2 (ja) |
EP (1) | EP1551495A4 (ja) |
JP (1) | JP2006502213A (ja) |
KR (1) | KR20050071565A (ja) |
CN (1) | CN100582085C (ja) |
AU (1) | AU2003269466B2 (ja) |
BR (1) | BR0314554A (ja) |
CA (1) | CA2501318A1 (ja) |
IS (1) | IS7781A (ja) |
MX (1) | MXPA05003870A (ja) |
NO (1) | NO20052229L (ja) |
NZ (1) | NZ539106A (ja) |
RU (1) | RU2337093C2 (ja) |
WO (1) | WO2004032824A2 (ja) |
ZA (1) | ZA200502613B (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
WO2008106092A1 (en) * | 2007-02-26 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
EP2117301A4 (en) * | 2007-02-26 | 2010-04-14 | Yeda Res & Dev | USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS |
WO2009042440A1 (en) * | 2007-09-28 | 2009-04-02 | Cortria Corporation | 1-methyl nicotinamide and derivatives for treatment of gastric injury |
US8334240B2 (en) | 2008-10-06 | 2012-12-18 | Nalco Company | Compositions and methods for inhibiting the agglomeration of hydrates in a process |
US8105987B2 (en) | 2008-10-06 | 2012-01-31 | Nalco Company | Corrosion inhibitors for an aqueous medium |
US8329620B2 (en) * | 2008-10-06 | 2012-12-11 | Nalco Company | Compositions and methods for inhibiting the agglomeration of hydrates |
US8105988B2 (en) | 2008-10-06 | 2012-01-31 | Nalco Company | Corrosion inhibitors for a fluid |
US8921478B2 (en) | 2008-10-17 | 2014-12-30 | Nalco Company | Method of controlling gas hydrates in fluid systems |
US10392573B2 (en) | 2008-10-17 | 2019-08-27 | Ecolab Usa Inc. | Method of controlling gas hydrates in fluid systems |
US8288323B2 (en) | 2009-03-02 | 2012-10-16 | Nalco Company | Compositions containing amide surfactants and methods for inhibiting the formation of hydrate agglomerates |
US8618025B2 (en) | 2010-12-16 | 2013-12-31 | Nalco Company | Composition and method for reducing hydrate agglomeration |
US9505707B2 (en) | 2010-12-22 | 2016-11-29 | Nalco Company | Composition and method for reducing hydrate agglomeration |
US20150157588A1 (en) * | 2012-07-05 | 2015-06-11 | Yeda Research And Development Co., Ltd. | Pharmaceutical Composition Comprising Amino-Phenyl-Acetic Acid Octadec-(Z)-9-enyl Ester and Use Thereof for Treating Tumors |
US20140248371A1 (en) | 2013-01-10 | 2014-09-04 | Carmel-Haifa University Economic Corp. Ltd. | Spalax fibroblast-derived anti-cancer agents |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) * | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
CH448122A (de) * | 1963-10-14 | 1967-12-15 | Hoffmann La Roche | Verfahren zur Herstellung von Estern |
US3592930A (en) * | 1968-07-19 | 1971-07-13 | Syntex Corp | Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle |
US3629111A (en) * | 1970-10-02 | 1971-12-21 | Olin Corp | Hydraulic fluids containing novel inhibitor compositions |
US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
DE2234399A1 (de) * | 1972-07-17 | 1974-01-31 | Thomae Gmbh Dr K | Hautschutzmittel |
NO761120L (ja) * | 1975-04-07 | 1976-10-08 | Ici Ltd | |
FR2383662A1 (fr) * | 1977-03-15 | 1978-10-13 | Cassenne Lab Sa | Nouvelles compositions a usage cosmetique |
FR2420545A1 (fr) | 1978-03-20 | 1979-10-19 | Anvar | Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques |
US4258029A (en) * | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
EP0064366A1 (en) * | 1981-04-29 | 1982-11-10 | Beecham Group Plc | Pharmaceutical compositions |
JPS5892607A (ja) * | 1981-11-26 | 1983-06-02 | Lion Corp | 毛髪化粧料 |
DE3482551D1 (de) * | 1983-10-26 | 1990-07-26 | Kanebo Ltd | Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung. |
US4749694A (en) * | 1984-04-26 | 1988-06-07 | Merck & Co., Inc. | Novel lysine esters used as absorption |
JPS61103826A (ja) | 1984-10-25 | 1986-05-22 | Kao Corp | 抗炎症剤 |
JPS61226977A (ja) * | 1985-03-30 | 1986-10-08 | Toshiba Corp | 発光素子 |
JP2522682B2 (ja) * | 1987-12-22 | 1996-08-07 | コニカ株式会社 | 感度の高いハロゲン化銀写真感光材料 |
JPH01190798A (ja) * | 1988-01-27 | 1989-07-31 | Kao Corp | 漂白剤組成物 |
JP2819415B2 (ja) * | 1988-06-03 | 1998-10-30 | 富山化学工業株式会社 | 養毛剤 |
CH679119A5 (ja) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
JP2857882B2 (ja) * | 1988-11-02 | 1999-02-17 | 富山化学工業株式会社 | ピロキシカムのプラスター剤 |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
ATE158950T1 (de) | 1989-07-14 | 1997-10-15 | Autoimmune Inc | Behandlung der autoimmunen uveoretinitis in menschen |
US5194451A (en) * | 1989-11-02 | 1993-03-16 | Katz David H | Systemic anti-inflammatory treatment |
IE904098A1 (en) * | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
JPH03170405A (ja) * | 1989-11-29 | 1991-07-24 | Nippon Oil & Fats Co Ltd | 魚類の誘引剤 |
IL97985A0 (en) * | 1990-05-07 | 1992-06-21 | North American Vaccine Inc | Improved vaccine compositions |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
MX9301789A (es) | 1992-04-03 | 1993-10-01 | Iaf Biochem Int | Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora. |
JP3211987B2 (ja) * | 1992-07-31 | 2001-09-25 | ソニー株式会社 | 磁気記録媒体 |
JPH0825857B2 (ja) * | 1993-04-28 | 1996-03-13 | 株式会社資生堂 | アミノ酸長鎖アルキルエステル化タンパクからなる毛髪処理剤 |
US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
JP3413303B2 (ja) * | 1995-01-20 | 2003-06-03 | 花王株式会社 | 液体柔軟仕上剤組成物 |
AU5360796A (en) | 1995-03-09 | 1996-10-02 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
US5945401A (en) | 1995-06-23 | 1999-08-31 | Conlon; Paul J. | Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof |
TW355153B (en) * | 1996-05-21 | 1999-04-01 | Toshiba Machine Co Ltd | A method for leveling abrasive cloth and device for the same |
EP1001759B1 (en) | 1996-09-17 | 2005-07-20 | Avanir Pharmaceuticals | Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides |
JPH10101630A (ja) * | 1996-09-30 | 1998-04-21 | Sankyo Co Ltd | 新規化合物B−5354a、B−5354b及びB−5354c |
NZ334852A (en) | 1996-10-11 | 2001-05-25 | Scotia Holdings Plc | Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia |
US5910306A (en) * | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
US6210700B1 (en) * | 1997-01-14 | 2001-04-03 | Novartis Nutrition Ag | Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy |
GB9710351D0 (en) | 1997-05-20 | 1997-07-16 | Scotia Holdings Plc | Glucosamine fatty acids |
US6242426B1 (en) | 1997-07-25 | 2001-06-05 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
US6114337A (en) * | 1998-11-27 | 2000-09-05 | Pugliese; Peter T. | Zwitteronic-fatty acid compounds having anti-inflammatory properties |
EP0919230A1 (en) * | 1997-12-01 | 1999-06-02 | Societe Des Produits Nestle S.A. | NMIFA's as anti-inflammatory agents in superficial mammal tissues |
US5968524A (en) * | 1997-12-23 | 1999-10-19 | Genesis Research & Development Corp. | Methods and compounds for the treatment of immunologically-mediated psoriasis |
PL342517A1 (en) | 1998-02-23 | 2001-06-18 | Neurocrine Biosciences | Methods of treating diabetes employing peptidic insulin analoques |
JPH11343235A (ja) | 1998-04-02 | 1999-12-14 | Ajinomoto Co Inc | アミノ酸誘導体および炎症因子活性化抑制剤 |
TW544310B (en) * | 1998-04-02 | 2003-08-01 | Ajinomoto Kk | Amino acid derivatives and anti-inflammatory agents |
AU7240398A (en) * | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
DE19828352A1 (de) * | 1998-06-25 | 1999-12-30 | Clariant Gmbh | Synergistische Mischungen von Phosphorsäureestern mit Carbonsäuren oder Carbonsäurederivaten als Asphalten-Dispergatoren |
US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
PT1194109E (pt) | 1999-06-25 | 2004-12-31 | Durham Pharmaceuticals Ltd | Formulacoes topicas compreendendo agentes de penetracao na pele e utilizacao dasmesmas |
JP2002097137A (ja) * | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および/または治療剤 |
DE10043196B4 (de) | 2000-09-01 | 2008-10-02 | W.C. Heraeus Gmbh | Glaskeramikmasse und Verwendung der Glaskeramikmasse |
JP4350288B2 (ja) * | 2000-09-21 | 2009-10-21 | 花王株式会社 | ベタインエステルの製造法 |
GB2393722A (en) * | 2001-02-13 | 2004-04-07 | Schlumberger Holdings | Cleavable surfactants which may be useful in viscoelastic compositions for oil-field applications |
JP2002241317A (ja) * | 2001-02-20 | 2002-08-28 | Hirotaka Ihara | 光学活性認識剤、それを用いた光学分割カラム充填剤および光学分割方法 |
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
US6943197B2 (en) * | 2002-06-21 | 2005-09-13 | Howard I. Maibach | Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses |
KR100900448B1 (ko) * | 2002-07-09 | 2009-06-02 | 엘지전자 주식회사 | 고밀도 광디스크의 패킷 엔코딩 타임 스탬프 기록방법 |
EP2117301A4 (en) | 2007-02-26 | 2010-04-14 | Yeda Res & Dev | USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS |
WO2008106092A1 (en) | 2007-02-26 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
-
2003
- 2003-10-09 NZ NZ539106A patent/NZ539106A/en unknown
- 2003-10-09 CN CN200380101149A patent/CN100582085C/zh not_active Expired - Fee Related
- 2003-10-09 CA CA002501318A patent/CA2501318A1/en not_active Abandoned
- 2003-10-09 KR KR1020057006181A patent/KR20050071565A/ko not_active Application Discontinuation
- 2003-10-09 EP EP03751246A patent/EP1551495A4/en not_active Withdrawn
- 2003-10-09 ZA ZA200502613A patent/ZA200502613B/xx unknown
- 2003-10-09 BR BR0314554-9A patent/BR0314554A/pt not_active IP Right Cessation
- 2003-10-09 AU AU2003269466A patent/AU2003269466B2/en not_active Ceased
- 2003-10-09 MX MXPA05003870A patent/MXPA05003870A/es active IP Right Grant
- 2003-10-09 US US10/530,776 patent/US8987263B2/en not_active Expired - Fee Related
- 2003-10-09 RU RU2005114374/04A patent/RU2337093C2/ru not_active IP Right Cessation
- 2003-10-09 WO PCT/IL2003/000820 patent/WO2004032824A2/en active Application Filing
- 2003-10-09 JP JP2004542766A patent/JP2006502213A/ja active Pending
-
2005
- 2005-03-31 IS IS7781A patent/IS7781A/is unknown
- 2005-05-09 NO NO20052229A patent/NO20052229L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003269466A1 (en) | 2004-05-04 |
US8987263B2 (en) | 2015-03-24 |
NZ539106A (en) | 2007-02-23 |
NO20052229D0 (no) | 2005-05-09 |
RU2337093C2 (ru) | 2008-10-27 |
KR20050071565A (ko) | 2005-07-07 |
CA2501318A1 (en) | 2004-04-22 |
NO20052229L (no) | 2005-07-06 |
BR0314554A (pt) | 2005-08-09 |
IS7781A (is) | 2005-03-31 |
EP1551495A2 (en) | 2005-07-13 |
US20060173053A1 (en) | 2006-08-03 |
CN100582085C (zh) | 2010-01-20 |
WO2004032824A2 (en) | 2004-04-22 |
JP2006502213A (ja) | 2006-01-19 |
RU2005114374A (ru) | 2006-02-27 |
MXPA05003870A (es) | 2005-06-22 |
AU2003269466B2 (en) | 2009-08-20 |
EP1551495A4 (en) | 2010-06-02 |
WO2004032824A3 (en) | 2004-08-26 |
CN1703394A (zh) | 2005-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7781A (is) | Basískir esterar úr fitu alkóhólum og notkun þeirra sem bólgueyðandi eða ónæmisstýrandi miðlar | |
HK1157760A1 (en) | Benzimidazol-carbonyl-pyridinyl-amino-propionic acid ethyl ester hemihydrate and use thereof | |
EP1479666A4 (en) | ESTER CONNECTION AND THEIR MEDICAL USE | |
IL171501A (en) | Genetically engineered cutaneous microorganisms and their use | |
PL1699449T3 (pl) | Zastosowanie kompozycji kwasów tłuszczowych obejmującej co najmniej jeden z EPA i DHA lub jakąkolwiek ich kombinację | |
GB2409644B (en) | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof | |
HK1073650A1 (en) | Methods for producing substituted acrylic acid esters and use of the latter for producing substituted | |
EP1625140A4 (en) | BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF | |
HUP0303881A3 (en) | Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation | |
PL377614A1 (pl) | Kompozycje zawierające kwasy tłuszczowe i aminokwasy | |
EP1551384A4 (en) | R-NSAID ESTERS AND ITS USE | |
AU2003291016A1 (en) | Glyceride compositions and methods of making and using same | |
AU2003257937A8 (en) | Methods and compositions for treatment of dermal conditions | |
HK1070558A1 (en) | Co-beadlet of dha and rosemary and methods of use | |
AU2003301240A8 (en) | Skin cleanser compositions and methods of use | |
AU2003217759A8 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
AU2003225651A1 (en) | Nematicidal fatty acid and fatty acid ester related compounds | |
IL162937A0 (en) | Pravastatin pharmaceutical formulations and methods of their use | |
AU2003222083A1 (en) | Acid and ester compounds and methods of using the same | |
HUP0303796A3 (en) | Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers | |
AU2003239868A8 (en) | Sunscreen compositions and methods of use thereof | |
ATE439362T1 (de) | Ester in position 20 von camptothecinen | |
IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
AU2002308979A1 (en) | Acrylic esters and use thereof | |
AU2003301819A8 (en) | Compositions and methods for prevention of photoaging |